FDA approves Takeda's Alunbrig

FDA granted accelerated approval to Alunbrig brigatinib (AP26113) from Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) to treat metastatic anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) in patients who have progressed on, or are intolerant to, Xalkori crizotinib. Takeda said it plans to make Alunbrig available "as soon as possible" with a list price of $14,250 per cycle for a 30-day supply...